Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials

BACKGROUND/AIMS: Numerous reasons have been identified for why U.S.-based principal investigators choose to not continue participating in FDA-regulated trials. However, unexplored are reasons why a substantial number of principal investigators, facing the same challenges, remain engaged in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Dombeck, Carrie B., Hinkley, Terri, Fordyce, Christopher B., Blanchard, Katelyn, Roe, Matthew T., Corneli, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926102/
https://www.ncbi.nlm.nih.gov/pubmed/31890985
http://dx.doi.org/10.1016/j.conctc.2019.100502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926102/
https://www.ncbi.nlm.nih.gov/pubmed/31890985
http://dx.doi.org/10.1016/j.conctc.2019.100502

Ejemplares similares